References

1. Poole R, et al. (2017). Coffee consumption and health:umbrella review of meta-analyses of multiple health outcomes. BMJ. 22;359:j5024.
2. European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA). (2015). Scientific opinion on the safety of caffeine. EFSA Journal. 13(5):4102.
3. Xie C, et al. (2018). Coffee consumption and risk of hypertension: a systematic review and dose-response meta-analysis of cohort studies. J Hum Hypertens. 32(2):83-93.
4. Svatun ÅL, et al. (2022). Association between espresso coffee and serum total cholesterol: the Tromsø Study 2015-2016. Open Heart. 9(1):e001946.
5. Ding M, et al (2014). Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circ. 129(6):643-59.
6. Crippa A, et al. (2014). Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis. Am J Epidemiol.180(8):763-75.
7.  Rodriguez Artalejo F & Lopez Garcia E. (2017).Coffee Consumption and Cardiovascular Disease: A condensed review of epidemiological evidence and mechanisms, JAgric Fd Chem. 66(21):5257-63.
8. O’Keefe JH, et al. (2018). Coffee for cardioprotection and longevity. Prog Cardiovasc Dis.61(1):38-42.
9. Ribeiro EM, et al. (2020). Safety of coffee consumption after myocardial infarction: A systematic review and meta-analysis .Nutr Metab Cardiovasc Dis.30(12):2146-58.
10. Simon J, et al. (2021). Association of daily coffee consumption with cardiovascular health – results from the UK Biobank. Euro Heart J. 42:724;2416.
11. Chieng D, et al. (2022). Effects of habitual coffee consumption on incident cardiovascular disease, arrhythmia, and mortality:findings from UK biobank. J Am Coll Cardiol. 79(9):1455.
12. European Society of Cardiology (ESC). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart Jour. 42:3227-337.
13. Timmis A, et al. (2020). European Society of Cardiology: Cardiovascular. Disease statistics 2019. Euro Heart J. 41:12;85.
14. European Heart Network, ‘European cardiovascular disease statistics 2017’. Available at: http://www.ehnheart.org/cvd-statistics/cvd-statistics-2017.html.
15. van Dam R. (2008). Combined impact of lifestyle factors on mortality: prospective cohort study in US women. BMJ. 337:a1440.
16. Mozaffarian D, et al. (2008): Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circ. 117(23):3031-8.
17. Bodar V, et al. (2020). Coffee consumption and risk of heart failure in the Physicians' Health study. Clin Nutr. ESPEN. 40:133-7.
18. Stevens LM, et al. (2021). Association between coffee intake and incident heart failure risk: a machine learning analysis of the FHS,the ARIC Study, and the CHS Circulation: Heart Failure. 14:e006799.
19. Hypponen E & Zhou A. (2021). Cardiovascular symptoms affect the patterns of habitual coffee consumption. Am J Clin Nutr. 114(1):214-9.
20. van Dam RM, et al. (2020). Coffee, Caffeine, and Health. N Engl J Med. 383:369-78.
21. van Dam RM & Hu FB. (2022). Caffeine consumption and cardiovascular health. Nat Rev Cardiol. 19:429–30.
22. Tikhonoff V, et al. (2022).Prognostic cut-off values of caffeine and cardiovascular events in a cohort of unselected men and women from general population. Abstract presented at ESC congress.
23. Xie C, et al. (2018). Coffee consumption and risk of hypertension: a systematic review and dose-response meta-analysis of cohort studies. J Hum Hypertens. 32(2):83-93.
24. D’Elia L, et al. (2019). Coffee consumption and risk of hypertension: a dose-response meta-analysis of prospective studies. Eur J Nutr. 58(1):271-80.
25. Surman S & Oparil S. (2021). Coffee and arterial hypertension. Curr Hypertens Rep. 23(7):38.
26. Borghi C, et al. (2020). Nutraceuticals and blood pressure control: a European Society of Hypertension (EHJ) position document. J Hypertens. 38(5):799-812.
27. Cai L, et al. (2012) The effect of coffee consumption on serum lipids: a meta-analysis of randomised controlled trials. Eur J Clin Nutr. 66(8):872-7.
28. Svatun ÅL, et al. (2022). Association between espresso coffee and serum total cholesterol: the Tromsø Study 2015-2016. Open Heart. 9(1):e001946.
29. Krittanawong C, et al. (2021). Is caffeine or coffee consumption a risk for new-onset atrial fibrillation? A systematic review and meta-analysis. Eur J Prev Cardiol. 28(12):e13-5.
30. Buscemi S, et al. (2010): Acute effects of coffee on endothelial function in healthy subjects. Eur J Clin Nutr. 64(5):483-9.
31. Buscemi S, et al. (2010). Coffee and endothelial function: a battle between caffeine and antioxidants. Eur J Clin Nutr. 64:1242-3.
32. Aqudelo-Ochoa GM. (2016). Coffee consumption increases the antioxidant capacity of plasma and has no effect on the lipid profile or vascular function in healthy adults in a randomized controlled trial. J Nutr. 146(3):524-31.
33. Refsum H, et al. (2006). The Hordaland Homocysteine study: a community based study of homocysteine, its determinants, and associations with disease. J Nutr. 136:6(suppl);17731S-40S.
34. Henkey GJ & Eikelboom JW. (1999). Homocysteine and vascular disease. Lancet. 354:407-13.
35. Folsom AR, et al. (1998). Prospective study of coronary heart disease incidence in relation to fasting homocysteine, related polymorphisms, and B vitamins: the atherosclerosis risk in communities (ARIC) study. Circulation. 98:204-10.
36. Fallon UB, et al. (2001). Homocysteine and coronary heart disease in the Caerphilly cohort: a 10-year follow up. Heart. 85:53-158.
37. Higdon JV & Frei B. (2006). coffee and health: a review of recent human research. Crit Revs Fd Sci Nut. 46:101-23.
38. Grubben MJ, et al. (2000). Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers: a randomised trial. AJCN. 71:448-84.
39. Urgert RA, et al. (2000). Heavy coffee consumption and plasma homocysteine: a randomised controlled trial in healthy volunteers. AJCN. 72:1107-10.
40. Christensen B, et al. (2001). Abstention from filtered coffee reduces concentrations of plasma homocysteine and serum cholesterol – a randomised controlled trial. AJCN. 74(3):302-7.
41. Espositio F, et al. (2003): Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects. Aliment Pharmacol Therapy. 17:595-601.V
42. Verhoef P, et al. (2002). Contribution of caffeine to the homocysteine-raising  effect of coffee: a randomised controlled trial in humans. AJCN. 76:1244-8.
43. Olthof MR, et al. (2001). Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. AJCN. 7(737):532-8.
44. Zhang W, et al. (2009). Coffee consumption and risk ofcardiovascular disease and all-cause mortality among men with type 2 diabetes. Diabetes Care. 32:1043-5.
45. Mukanal KJ, et al. (2009): Coffee consumption and mortality after acute myocardial infarction: the Stockholm Heart Epidemiology Program. Am Heart J. 157:495-501.
46. Palatini P, et al. (2009). CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertension. 27(8):1594-601.
47. Lopez-Garcia E, et al. (2016). Habitual coffee consumption and 24-hour blood pressure  control in older adults with hypertension. Clin Nutr. 35(6):1457-63.
48. Notara V, et al. (2015). The role of coffee consumption on the 10-year (2004-2014) acute coronary syndrome (ACS) Incidence among cardiac patients: the GREECS observational study. Int J Fd Sci &Nutr. 66(6):722-8.
49. Natella F, et al. (2002). Coffee drinking influences plasma antioxidant capacity in humans. Food Chem. 50:6211-16.
50. Nystad T, et al. (2010). The effect of coffee consumption on serum total cholesterol in the Sami & Norwegian populations. Public Health Nutrition. 13(11):1818-25.
51. Correa TAF, et al. (2013). Paper filtered coffee increases cholesterol and inflammation biomarkers independent of roasting degree. Nutrition. 29:977-81.
52. Daneschvar HL, et al. (2021). Impact of coffee consumption on physiological markers of cardiovascular risk: a systematic review. Am J Med. 134(5):626-36;e2.
53. Nehlig A. (2018). Inter individual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacol Rev. 70(2):384-411.

‍